Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Allergic Rhinitis Drugs Market

Allergic Rhinitis Drugs Market Share

Report ID: GMI5413
Published Date: Jan 2023
Report Format: PDF

Download Free Sample

Allergic Rhinitis Drugs Market Share

Merck & Co.
GlaxoSmithKline PLC
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim
Unichem Laboratories
Stallergenes Greer
Sanofi S.A.
Alcon (Novartis AG)
Johnson & Johnson
Meda AB
Mylan NV
Allergy Therapeutics PLC
ALK-Abelló A/S
Glenmark Pharmaceuticals Ltd
Bayer AG
Dr. Reddy’s Laboratories
Adamis Pharmaceuticals
Sun Pharmaceuticals

are key participants involved in the market. These firms focus on thorough R&D programs to expand their product portfolio and propel their market position.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for allergic rhinitis drugs was valued at more than USD 12 billion in 2022 and is set to progress at over 2.5% CAGR over the next 10 years owing to technological advancements in the field of allergy diagnosis and treatment.

Online channel segment is foreseen to reach over USD 4 billion by the end of 2032 on account of the availability of swift service, beneficial discounts & offers from various manufacturers, and the strong preference of elderly patients.

Oral segment is poised to garner more than USD 6.5 billion in revenue by 2032 as a result of its high level of convenience, low cost, and non-invasive approach.

Allergic rhinitis drugs market in North America accounted for more than 37% of the revenue share in 2022 due to soaring technological developments in treatment methods and rising healthcare expenditures in the region.